Trial · NCT00331682
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
NCT00331682, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2014-01-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer. Trials, record NCT00331682. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00331682
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
- NCT number
- NCT00331682
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- alvocidib, docetaxel
- First posted
- 2006-05-31
- Last updated
- 2014-05-28
- Results first posted
- 2014-01-10
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate as Measured by RECIST Criteria | Up to 2 years | Objective response rate as measured by RECIST criteria |
| Secondary | Time to Progression | Between the start of treatment until the criteria for progression are met, assessed up to 2 years | Will be computed using Kaplan-Meier methods. |
| Secondary | Overall Survival | Between the start of treatment until patient death, assessed up to 2 years | Will be computed using Kaplan-Meier methods. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate as Measured by RECIST Criteria | Up to 2 years | participants | NUMBER | |
| SECONDARY | Time to Progression | Between the start of treatment until the criteria for progression are met, assessed up to 2 years | weeks | MEDIAN | |
| SECONDARY | Overall Survival | Between the start of treatment until patient death, assessed up to 2 years | months | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate as Measured by RECIST Criteria | Docetaxel and Flavopiridol | Stable Disease | 3 | participants | |
| Objective Response Rate as Measured by RECIST Criteria | Docetaxel and Flavopiridol | Progression of Disease | 6 | participants | |
| Time to Progression | Docetaxel and Flavopiridol | 8 | Full Range 7 to 14 | weeks | |
| Overall Survival | Docetaxel and Flavopiridol | 4.2 | Full Range 2.8 to 6.9 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Docetaxel and Flavopiridol | 10 | |
| Overall Study | COMPLETED | Docetaxel and Flavopiridol | 9 | |
| Overall Study | NOT COMPLETED | Docetaxel and Flavopiridol | 1 |
Source ClinicalTrials.gov
Adverse events61
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | Docetaxel and Flavopiridol | 1 | 9 | 1 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Docetaxel and Flavopiridol | 5 | 9 | 5 |
| other | Alkaline phosphatase increased | Investigations | Docetaxel and Flavopiridol | 2 | 9 | 2 |
| other | Anorexia | Metabolism and nutrition disorders | Docetaxel and Flavopiridol | 1 | 9 | 1 |
| other | Blood bilirubin increased | Investigations | Docetaxel and Flavopiridol | 1 | 9 | 1 |
| other | Hypocalcemia | Metabolism and nutrition disorders | Docetaxel and Flavopiridol | 1 | 9 | 1 |
| other | Cardiac troponin I increased | Investigations | Docetaxel and Flavopiridol | 1 | 9 | 1 |
| other | Constipation | Gastrointestinal disorders | Docetaxel and Flavopiridol | 1 | 9 | 1 |
| other | Creatinine increased | Investigations | Docetaxel and Flavopiridol | 1 | 9 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Docetaxel and Flavopiridol | 4 | 9 | 4 |
1 to 10 of 61Source ClinicalTrials.gov
See all 61 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Docetaxel and Flavopiridol | ||
| Total, other adverse events | Docetaxel and Flavopiridol | 9 | 9 |
| Total, serious adverse events | Docetaxel and Flavopiridol | 10 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01CA067819 | Clinical Trials of Flavopiridol with Chemotherapy | SCHWARTZ, GARY K | SLOAN-KETTERING INST CAN RESEARCH | NATIONAL CANCER INSTITUTE | 1996 to 2008 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00331682
GET https://conductscience.org/api/trials/v1/NCT00331682/events?page=2